| Document |
Document Title |
|
WO/2024/072897A1 |
Provided herein are methods, compositions, reaction mixtures, kits and systems for measuring protease activities, detecting protein-protein interactions, and identifying signaling molecules that induce protein-protein interactions. In pa...
|
|
WO/2024/065297A1 |
Embodiments of the present invention provide a chimeric antigen receptor with a light chain variable region having a sequence set forth in SEQ ID NO: 1 and a heavy chain variable region having a sequence set forth in SEQ ID NO: 2. The ch...
|
|
WO/2024/073715A2 |
Described herein are gene-targeted therapies and compositions that can include a vessel-specific viral vector, preferably in combination with a HDAC9-derived promoter to transduce SMC and deliver a base editor that corrects mutant allele...
|
|
WO/2024/067759A1 |
The present invention relates to a novel humanized anti-human CLDN18.2 antibody and an antigen-binding fragment thereof. The present invention also relates to a preparation method for the antibody. The present invention further relates t...
|
|
WO/2024/073689A1 |
Synthetic polynucleotide libraries may include a plurality of polynucleotides. The polynucleotides may comprise DNA and may be configured to hybridize with one or more regions of target nucleic acids. The target nucleic acids may compris...
|
|
WO/2024/066819A1 |
Disclosed is a method for producing 3-hydroxypropionic acid and acrylic acid by means of fermentation. The present invention provides a recombinant Corynebacterium glutamicum. The aldehyde dehydrogenase gene ald of the microorganism is u...
|
|
WO/2024/072882A1 |
Provided herein are vectors including a polynucleotide encoding an α9L9'T protein, pharmaceutical compositions including the vector including a polynucleotide encoding an α9L9'T protein, and methods of use thereof. The methods of use i...
|
|
WO/2024/067821A1 |
Provided is a modified cell, wherein the modified cell is formed by binding a complex protein to a cell surface marker molecule of the modified cell. The complex protein comprises a part specifically binding to the cell surface marker mo...
|
|
WO/2024/065651A1 |
The present invention relates to a method for loading a dimer CD24 into an HEK293 cell exosome with ADAM10 gene knocked out. By means of loading a dimer CD24 and/or ApoE protein into an HEK293 cell exosome with ADAM10 gene knocked out, t...
|
|
WO/2024/072775A1 |
The present disclosure provides devices, systems, kits, and related methods for isolating DNA from a sample (e.g., plasma) using RNA-guided DNA binding proteins (e.g., Cas proteins). Particularly, the disclosure provides devices, systems...
|
|
WO/2024/073726A2 |
The present disclosure relates to engineered cells expressing heterologous MUC1, MUC1-C or MUC1-C cytoplasmic domain for generating induced pluripotent stem cells that are autologous to a subject.
|
|
WO/2024/071279A1 |
Provided is a super-high-molecular gamma-polyglutamic acid having an average molecular weight of at least 20 million. Also provided is a Bacillus genus bacterium variant strain that can produce said super-high-molecular γ-PGA. Further p...
|
|
WO/2024/067747A1 |
The present invention provides a 5'-UTR sequence capable of improving the translation efficiency of a protein coding region, and a use thereof. The 5'-UTR sequence of the present invention can improve the translation efficiency of the pr...
|
|
WO/2024/071924A1 |
In one embodiment of the present invention, the present invention relates to an exosome and uses thereof, the exosome comprising a protein that induces cell death and a polypeptide that increases the half-life of an exosome. The exosome ...
|
|
WO/2024/067861A1 |
Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, com...
|
|
WO/2024/067644A1 |
A method for cell-free preparation of an mRNA transcription template, the method comprising the following steps: 1) in the presence of at least one type of primer and while promoting the amplification of a DNA template, causing contact o...
|
|
WO/2024/065657A1 |
Embodiments of the present disclosure provide access control method and access control apparatus. The access control method for controlling access right of a person for entering a place physically may include: obtaining an identity infor...
|
|
WO/2024/073570A1 |
Provided are materials and methods for rejuvenating senescent cells. Senescent cells are transduced with a viral vector to express Oct4, Sox2, and Klf4 proteins for partial cell reprogramming and a dominant negative NFκBIA protein to su...
|
|
WO/2024/065268A1 |
Provided is a single-domain antibody or antigen-binding fragment capable of identifying ANG-2, and a multispecific antibody. The antibody or antigen-binding fragment has a heavy chain variable region as represented by any one of SEQ ID N...
|
|
WO/2024/069464A1 |
The present invention discloses a method to quantify tRNA abundance and tRNA modifications in an RNA sample that comprises contacting RNA with oligonucleotides in the presence of a ligating agent and performing nanopore direct sequencing...
|
|
WO/2024/067770A1 |
Provided is a lentivirus packaging titer kit. An existing virus packaging vector is modified to construct a high-virus packaging titer kit. For conventional virus helper plasmids, a replication origin, a promoter, a terminator, an enhanc...
|
|
WO/2024/066416A1 |
Provided are a CXCL-BPI fusion protein capable of being used for treating gram-negative bacterial infections, an encoding nucleic acid thereof, an expression and preparation method therefor, and use thereof for preparing a pharmaceutical...
|
|
WO/2024/067540A1 |
Disclosed is a genetically engineered HSV-1, comprising a deletion of an internal inverted repeat region, and a deletion in an HVEM binding domain of gD. The HSV-1 comprises a first polynucleotide encoding a Fc-less bispecific antibody i...
|
|
WO/2024/072820A1 |
In alternative embodiments, provided are compositions, including compositions, products of manufacture and kits, and methods, for manipulating, and in particular, augmenting or increasing, T cell activity in vitro and in vivo, by for exa...
|
|
WO/2024/065042A1 |
Provided are novel sulfur-containing lipids and nanoparticles containing such lipids and a cargo molecule, such as a nucleic acid, methods to formulate said lipids with nucleic acids to produce lipid nanoparticles and chemical routes for...
|
|
WO/2024/068754A1 |
The invention relates to a system (1) for continuous manufacture of biomolecules comprising feed tanks (2) suitable for storing products and a reaction chamber (4) designed to be fed with products from said feed tanks which form in the r...
|
|
WO/2024/073709A2 |
The technology described herein relates modified oligonucleotides and double-stranded RNAs, e.g., siRNAs, compositions and kits comprising them and methods of their use for inhibiting target genes.
|
|
WO/2024/073114A1 |
The present disclosure relates to compositions of matter and methods used to activate effector nucleic acids and effector targets in vivo via a CRISPR-based cascade system. The compositions and methods achieve non-specific delivery of ca...
|
|
WO/2024/067086A1 |
Provided is a Bacillus licheniformis cell capable of being stably and repeatedly used for conversion and synthesis of D-allulose, which belongs to the field of biotechnology. D-allulose is a functional sugar with a high health value and ...
|
|
WO/2024/071180A1 |
Provided is a novel carrier for introducing a protein such as a Cas protein into cells. A carrier for a protein according to the present invention is characterized by containing vesicles of the fruit of the Malpighiaceae plant, wherein...
|
|
WO/2024/069144A1 |
The invention provides means and methods for treating, preventing or reversing retinal degeneration by RNA editing. The methods comprise administering to the subject a vector or a pair of complementary vectors that express a dCaslS-ADARn...
|
|
WO/2024/067725A1 |
Provided are a respiratory syncytial virus subtype B (RSV-B) recombinant F protein, a polynucleotide, a nucleic acid construct, an expression vector, a host cell, a stabilized trimer of the recombinant F protein, and an immunogenic compo...
|
|
WO/2024/071424A1 |
Provided is a vector or vector set for analyzing the function of a functional molecule, said vector or vector set comprising: a polynucleotide that codes for an expression system of a candidate molecule for the functional molecule; a pol...
|
|
WO/2024/071411A1 |
[Problem] To provide an immune cell induced from an iPS cell, to which a phenotype favorable to the migration or invasion of an immune cell to a solid tumor site and the proliferation and survive of an immune cell in a solid tumor is imp...
|
|
WO/2024/066780A1 |
Provided are a fusion type adeno-associated virus and a gene delivery effect thereof in the lung and eyes. The fusion type adeno-associated virus comprises a fusion peptide fragment formed by fusion of peptide fragments of serotype AAV1 ...
|
|
WO/2024/066083A1 |
The present invention relates to the technical field of biology, and in particular to a constant-temperature detection kit and detection method for detecting pathogens. The kit comprises an amplification system; the amplification system ...
|
|
WO/2024/073735A2 |
Provided herein are oligonucleotides (e.g., siRNA) targeting S6K1. Also provided are methods of treating a disease associated with S6K1 expression.
|
|
WO/2024/069581A1 |
Protein complexes including a cytidine deaminase and a helicase. In some embodiments, the cytidine deaminase is an altered cytidine deaminase. In some embodiments, the protein complex converts 5 methylcytosine to thymine. Kits, compositi...
|
|
WO/2024/069939A1 |
The present invention pertains to a nucleic acid amplification cartridge (10) including a reaction tank (20). Water-soluble beads BP including a nucleic acid amplification primer and water-soluble beads BE including a nucleic acid amplif...
|
|
WO/2024/070614A1 |
This test container is used for a nucleic acid amplification test executed in a nucleic acid amplification device. The test container comprises: a substrate; and a flowpath which is provided to the substrate and in which a sample contain...
|
|
WO/2024/065083A1 |
Disclosed in the present application is a method for testing the in-vivo drug efficacy of an IL-1α antibody in non-murine mammals. The method comprises administering IL-1α from non-murine mammals and an IL-1α antibody to be tested to ...
|
|
WO/2024/067764A1 |
The present invention provides a monoclonal antibody (especially a mouse, chimeric or humanized monoclonal antibody)/bispecific antibody or an antigen-binding fragment thereof. The antibody or the antigen-binding fragment thereof specifi...
|
|
WO/2024/071099A1 |
The present invention addresses the problem of providing a novel nucleic acid molecule capable of simultaneously achieving both a high gene regulatory effect and toxicity reduction. Provided is a nucleic acid molecule that contains a b...
|
|
WO/2024/066377A1 |
The present invention provides a VEGF and ANG-2 bispecific antibody and use thereof. The bispecific antibody comprises: a first binding region, the first binding region comprising a single-chain antibody, and the single-chain antibody ha...
|
|
WO/2024/065056A1 |
Antibody-drug conjugates (ADCs) comprising an antibody construct that specifically binds c-Met conjugated to one or more drugs, such as the auristatin analogue, compound (1), via a linker. Also described are anti-cMet antibody constructs...
|
|
WO/2024/071491A1 |
The present invention relates to a microorganism having a mycosporine-like amino acid producing ability and a method for producing mycosporine-like amino acids using same. According to one aspect of the present invention, when 3-deoxy-7-...
|
|
WO/2024/067796A1 |
Provided are a non-human animal expressing a human or chimeric (e.g. humanized) IL5 and/or IL5RA protein, and a use method therefor.
|
|
WO/2024/071437A1 |
The present invention relates to an epileptic model of a mammal. This epileptic model is obtained by a method including: (i) injecting an RNA-interfering shRNA having a sequence corresponding to base 194-212 of SEQ ID NO: 1 of a nucleic ...
|
|
WO/2024/067870A1 |
Provided are a targeting vector and a method for targeting same to a host cell. The vector comprises a first molecule that binds to an endocytosis receptor of the target cell and a second molecule that promotes the release of a substance...
|
|
WO/2024/067478A1 |
The present invention provides a method for measuring a single-molecule RNA force spectrum and a use thereof. The method comprises the following steps: 1) obtaining a handle chain: designing and synthesizing a specially modified handle c...
|
